The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of corticosteroid (CS) exposure on acquired resistance to immune checkpoint inhibitor (ICI) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC): A single centre experience.
 
Sowmya Cheruvu
Travel, Accommodations, Expenses - Novartis
 
Laura Marandino
Speakers' Bureau - Gilead Sciences; Merck
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Janssen
 
Ana Gutierrez
No Relationships to Disclose
 
Ha Mo Linh Le
No Relationships to Disclose
 
Carlo Andrea Bravi
No Relationships to Disclose
 
Diana I. Rosero
Speakers' Bureau - LEO Pharma
Travel, Accommodations, Expenses - Servier
 
Nalinie Joharatnam Hogan
No Relationships to Disclose
 
David Mcmahon
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - Pfizer; Takeda
 
Walter Cazzaniga
No Relationships to Disclose
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; GlaxoSmithKline; immatics; Pierre Fabre; Roche/Genentech